Mehmet Kemal Samur

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma.

Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson K, Avet-Loiseau H, Munshi N.

Blood Adv. 2023 Nov 14. 7(21):6599-6603. PMID: 37611163

Myeloma heterogeneity at cell resolution.

Samur MK.

Blood. 2023 Nov 09. 142(19):1582-1583. PMID: 37944180

Differentiation of BCMA-specific induced pluripotent stem cells into CD8aß+ T cells targeting multiple myeloma.

Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin D, Livak K, Li S, Tarannum M, Romee R, Samur MK, Munshi NC, Kaneko S, Ritz J, Anderson KC.

Blood. 2023 10 27. PMID: 37890146

Single-cell profiling in multiple myeloma: insights, problems, and promises.

Samur MK, Szalat R, Munshi NC.

Blood. 2023 07 27. 142(4):313-324. PMID: 37196627

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.

Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M.

Blood. 2023 Jun 08. 141(23):2841-2852. PMID: 36877894

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.

Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC.

Blood. 2023 05 25. 141(21):2599-2614. PMID: 36630605

Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.

Kumar S, Zhao J, Talluri S, Buon L, Mu S, Potluri LB, Liao C, Shi J, Chakraborty C, Gonzalez GB, Tai YT, Patel J, Pal J, Mashimo H, Samur MK, Munshi NC, Shammas MA.

Gastroenterology. 2023 08. 165(2):357-373. PMID: 37178737

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC.

Clin Cancer Res. 2023 05 01. 29(9):1807-1821. PMID: 36780189

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.

Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC.

Blood. 2023 04 06. 141(14):1724-1736. PMID: 36603186

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.

Stong N, Ortiz-Estévez M, Towfic F, Samur M, Agarwal A, Corre J, Flynt E, Munshi N, Avet-Loiseau H, Thakurta A.

Blood. 2023 03 30. 141(13):1574-1583. PMID: 35984902